Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Kidney Neoplasms 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

pembrolizumab 31Nivolumab 12Cyclophosphamide 10fludarabine 9aldesleukin 8atezolizumab 7durvalumab 6Magnetic Resonance Spectroscopy 6Trastuzumab 5Specimen Handling 5Paclitaxel 5Ipilimumab 5Docetaxel 5Biopsy 5fludarabine phosphate 4Radiotherapy 4Interleukin-2 4Gene Expression Profiling 4Carboplatin 4tisotumab vedotin 3cemiplimab 3aflibercept 3Polymerase Chain Reaction 3Immunoglobulin G 3Early Intervention, Educational 3Cisplatin 3Bevacizumab 3tremelimumab 2tislelizumab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Technetium Tc 99m Sestamibi × Genitourinary × Clear all
NCT00069160 2012-10-12

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
48 enrolled 13 charts
GenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡